170570-75-9: Celecoxib Bromo Impurity

Status: In-stock

It is a selective cyclooxygenase-2 inhibitor, By inhibiting prostaglandin synthesis non-steroidal anti-inflammatory drugs cause mucosal damage and ulceration. Celecoxib poses less of an ulceration risk than other NSAIDS, owing to its decreased effect on gastric mucosal prostaglandin synthesis when compared to placebo, also exerts anticancer effects by binding to the cadherin-11 protein, which is involved in the progression of tumors and inhibiting the 3 phosphoinositide-dependent kinase-1 signaling mechanism, which is used to treat osteoarthritis, rheumatoid arthritis, and to reduce polyps in familial adenomatous polyposis.

Request quotation

Additional information on CAS 170570-75-9

Catalogue No. VE007713
CAS No. 170570-75-9
Molecular Formula C17H13BrF3N3O2S
Molecular Weight 460.27 g/mol
Parent drug Celecoxib
IUPAC Name 4-(5-(4-(Bromomethyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
Synonyms N/A
References Xu, C., Gu, K., Yasen, Y., & Hou, Y. (2016). Efficacy and Safety of Celecoxib Therapy in Osteoarthritis. Medicine, 95(20), e3585. https://doi.org/10.1097/md.0000000000003585
Status In-stock

Request a quote

We Respond Within a Few Hours - Whether You're a New or Existing Client

Payment Made Simple: All major Credit/Debit cards accepted

Streamlined 3-Step Process from Quotes to Orders:

Product name:

170570-75-9: Celecoxib Bromo Impurity

"*" indicates required fields

Products quotation
This field is for validation purposes and should be left unchanged.